P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY

MLA

A. Tivey, et al. “P1141: Ibrutinib and Rituximab as First Line Therapy for Mantle Cell Lymphoma: A Multicentre, Real-World Uk Study.” HemaSphere, vol. 6, June 2022, pp. 1031–32. EBSCOhost, https://doi.org/10.1097/01.HS9.0000847432.95668.eb.

APA

A. Tivey, R. Shotton, T. A. Eyre, D. Lewis, N. Crosbie, E. Nga, R. Guerrero Camacho, W. Swe, H. Marr, C. Rees, S. Moule, T. Sutton, D. Wrench, N. Thomas, M. Wilson, J. Bailey, M. Prahladan, A. Hodson, M. Koppana, … K. Linton. (2022). P1141: Ibrutinib and Rituximab as First Line Therapy for Mantle Cell Lymphoma: A Multicentre, Real-World Uk Study. HemaSphere, 6, 1031–1032. https://doi.org/10.1097/01.HS9.0000847432.95668.eb

Chicago

A. Tivey, R. Shotton, T. A. Eyre, D. Lewis, N. Crosbie, E. Nga, R. Guerrero Camacho, et al. 2022. “P1141: Ibrutinib and Rituximab as First Line Therapy for Mantle Cell Lymphoma: A Multicentre, Real-World Uk Study.” HemaSphere 6 (June): 1031–32. doi:10.1097/01.HS9.0000847432.95668.eb.